Recombinant CD19 (B-Lymphocyte Marker) Antibody [CD19/4260R ]

Additional information

Catalog Number: 930-RBM10-IHC7
Host:

Reactivity:

Gene:

In Stock

Trial Size Available

Carrier-Free Available

In Stock
Catalog Number Formulation Size Price
930-RBM10-IHC7
7.0ml of Prediluted Antibody for IHC
7.0ml
$559.00
Flat Rate Domestic: $95 | Orders outside the US - Contact Us for Order Information | Ships next business day
  • IHC

Documents

Document Name
Datasheet Download Here
Material Safety Data Sheet Download Here

Applications & Dilutions

Applications Tested Dilutions Protocol Note
Immunohistochemistry (IHC) 1-2ug/ml IHC Protocol 30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Product Properties

Host
Rabbit
Applications
Species Reactivity
Clone
CD19/4260R
Isotype
IgG
Light Chain
Kappa
Cellular Localization
Cell surface
Gene Name
Positive Control
Human tonsil, lymph node or spleen.
Immunogen
Recombinant fragment of human CD19 protein (around aa300-556) (exact sequence is proprietary)
Expression System
CHO
Purification
Protein A
Storage & Stability
Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C.Antibody is stable for 24 months. Non-hazardous. No MSDS required.
Supplied as
7.0ml of Ready-to-Use for IHC staining of formalin-fixed paraffin-embedded tissues.
Limitations
This antibody is available for research use only and is not approved for use in diagnosis.

Related Antibodies

Other Information

Functions
Key References
Warranty
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
Entrez Gene ID
930
SwissProt
Chromosome Location
16p11.2
Mol. Weight of Antigen
95kDa
Alternate Names
B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CVID3; Leu-12; T-cell surface antigen Leu-12

Summary

CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Worry-Free Guarantee

Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.

Need Technical Help?

Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.